Boehringer Ingelheim Ditches Phase II Alzheimer's Program Post author:Sam Post published:February 8, 2018 Post category:BioPharma Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin. Source: BioSpace You Might Also Like What Biogen Wants in Return for Financial Assistance of Its $750,000 a Year Drug June 11, 2017 Edwards Lifesciences Gets Split Decision In UK Heart Valve Patent Spat With Boston Scientific March 2, 2017 What You Need to Know About Immune-Onc Therapeutics January 24, 2018
Edwards Lifesciences Gets Split Decision In UK Heart Valve Patent Spat With Boston Scientific March 2, 2017